{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:53:37Z","timestamp":1783464817700,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40265-025-02159-z","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T12:59:56Z","timestamp":1743857996000},"page":"833-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acoramidis: First Approval"],"prefix":"10.1007","volume":"85","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"2159_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.pcad.2024.01.013","volume":"82","author":"J Vaishnav","year":"2024","unstructured":"Vaishnav J, Brown E, Sharma K. Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy. Prog Cardiovasc Dis. 2024;82:113\u201324.","journal-title":"Prog Cardiovasc Dis"},{"issue":"19","key":"2159_CR2","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1021\/acschemneuro.0c00338","volume":"11","author":"S Zhou","year":"2020","unstructured":"Zhou S, Ge S, Zhang W, et al. Conventional molecular dynamics and metadynamics simulation studies of the binding and unbinding mechanism of TTR stabilizers AG10 and tafamidis. ACS Chem Neurosci. 2020;11(19):3025\u201335.","journal-title":"ACS Chem Neurosci"},{"issue":"17","key":"2159_CR3","doi-asserted-by":"publisher","first-page":"7862","DOI":"10.1021\/acs.jmedchem.8b00817","volume":"61","author":"M Miller","year":"2018","unstructured":"Miller M, Pal A, Albusairi W, et al. Enthalpy-driven stabilization of transthyretin by AG10 mimics a naturally occurring genetic variant that protects from transthyretin amyloidosis. J Med Chem. 2018;61(17):7862\u201376.","journal-title":"J Med Chem"},{"key":"2159_CR4","unstructured":"BridgeBio Pharma, Inc,. Attruby\u2122 (acoramidis), a near complete TTR stabilizer (\u226590%), approved by FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients [media release]. Nov 22 2024. https:\/\/bridgebio.com"},{"key":"2159_CR5","unstructured":"BridgeBio Pharma, Inc,. ATTRUBY\u2122 (acoramidis) tablets, for oral administration. US prescribing information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216540s000lbl.pdf. Accessed Nov 29, 2024"},{"key":"2159_CR6","unstructured":"BridgeBio Pharma, Inc,. Form 10-Q for the quarterly period ended September 30, 2024. SEC Filing Report 2024."},{"key":"2159_CR7","unstructured":"BridgeBio Pharma, Inc,. Form 10-K for fiscal year ended December 31, 2023. SEC Filing Report 2023."},{"key":"2159_CR8","unstructured":"BridgeBio Pharma, Inc,. BridgeBio Pharma, Inc. announces completion of merger with Eidos Therapeutics, Inc [media release]. 26 Jan 2021. https:\/\/bridgebio.com"},{"key":"2159_CR9","unstructured":"Alexion Pharmaceuticals. Alexion and BridgeBio announce Japanese license agreement for Eidos' transthyretin amyloidosis (ATTR) investigational medicine [media release]. 9 Sep 2019. https:\/\/alexion.com"},{"key":"2159_CR10","unstructured":"BridgeBio Pharma, Inc,. BridgeBio Pharma and Bayer announce European licensing agreement for acoramidis in ATTR-CM [media release]. 4 Mar 2024. https:\/\/bridgebio.com"},{"issue":"3","key":"2159_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jacc.2019.03.012","volume":"74","author":"DP Judge","year":"2019","unstructured":"Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285\u201395.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2159_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132\u201342.","journal-title":"N Engl J Med"},{"issue":"14","key":"2159_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMc2401669","volume":"390","author":"J Verbeeck","year":"2024","unstructured":"Verbeeck J, De Backer M, Buyse M. Acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(14):1345\u20136.","journal-title":"N Engl J Med"},{"issue":"S2","key":"2159_CR14","first-page":"498","volume":"26","author":"MH Hanna","year":"2024","unstructured":"Hanna MH, Arad MA, Gonzalez-Juanatey J, et al. Health-related quality of life in patients with symptomatic transthyretin amyloid cardiomyopathy treated with acoramidis: an EQ-5D analysis from the ATTRibute-CM study. Eur J Heart Fail. 2024;26(S2):498.","journal-title":"Eur J Heart Fail"},{"issue":"S2","key":"2159_CR15","first-page":"497","volume":"26","author":"M Fontana","year":"2024","unstructured":"Fontana M, Sperry BS, Kastritis EK, et al. Improved health-related quality of life in acoramidis-treated patients with ATTR-CM, demonstrated by improvements in KCCQ scores. Eur J Heart Fail. 2024;26(S2):497.","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"2159_CR16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012135","volume":"17","author":"Y Razvi","year":"2024","unstructured":"Razvi Y, Judge DP, Martinez-Naharro A, et al. Effect of acoramidis on myocardial structure and function in transthyretin amyloid cardiomyopathy: insights from the ATTRibute-CM cardiac magnetic resonance (CMR) substudy. Circ Heart Fail. 2024;17(12): e012135.","journal-title":"Circ Heart Fail"},{"key":"2159_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.072771","author":"DP Judge","year":"2024","unstructured":"Judge DP, Gillmore JD, Alexander KM, et al. Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM trial [online ahead of print]. Circulation. 2024. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072771.","journal-title":"Circulation"},{"key":"2159_CR18","unstructured":"European Medicines Agency. Beyonttra. 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/beyonttra. Accessed 2024."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02159-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02159-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02159-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:02:17Z","timestamp":1748012537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02159-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2159"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02159-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"5 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.Authorship and Conflict of InterestDuring the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}